Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Clinical Genomics hits a milestone in colon cancer prevention

Clinical Genomics
Posted on: 25 Aug 17

More than 25 million tests have been provided to patients globally for bowel cancer screening

 

Monday August 14th, 2017 (Sydney, Australia): Australian biotech success story Clinical Genomics Technologies Pty Ltd has celebrated a remarkable milestone after manufacturing its 25 millionth test kit for bowel cancer screening.

 

Developed in Australia, and based on the faecal immunochemical test (or FIT) methodology, this world-leading test is distributed internationally as “InSure FIT” and locally as “ColoVantage Home” through Australian GP’s and pharmacies.

 

In a recent report from the U.S. Multi-Society Task Force, faecal immunochemical tests, along with colonoscopy, were recommended as ‘first tier’ tests for screening for colorectal cancer.

 

Insure FIT and ColoVantage Home continue to be preferred by both doctors and consumers, due to the tests unique design and ease of use. This test uses a patented ‘Brush’ sampling technology to detect the presence of blood in water from the toilet bowl, instead of the user having to collect a stool or faecal sample; an unpleasant requirement normally associated with other at-home collection methods.

 

Manufactured in North Ryde in NSW Australia, the InSure FIT and ColoVantage Home brands are used by bowel cancer screening programs in the U.S.A., Australia, and around the world.

 

The test’s wide adoption both locally and internationally is evidence of its ease of use, while its effectiveness to accurately and reliably detect lower gastrointestinal bleeding is supported by years of research.

 

Bowel cancer is one of the leading causes of cancer-related deaths worldwide, accounting for more than 700,000 deaths each year.

 

According to Mark Boyle, President at Clinical Genomics, the company’s long term commitment to manufacturing and distributing bowel cancer screening tests has saved many thousands of lives over the last decade. “Above all we count this as a huge achievement, and are proud of the part we are playing to prevent deaths due to bowel cancer,” said Mr. Boyle.

 

About Clinical Genomics

Clinical Genomics is a privately held biotechnology company developing and marketing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 95 patents, Clinical Genomics sells colorectal cancer screening and monitoring solutions In 2016, Clinical Genomics launched Colvera™, a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects methylated DNA from two genes, BCAT1 and IKZF1. 

 

Clinical Genomics has offices and a CLIA-registered laboratory in Bridgewater NJ as well as FDA-registered and TGA-licensed IVD manufacturing in Edison, New Jersey and Sydney, Australia and a NATA-accredited laboratory in North Ryde, NSW Australia.

 

For more information, please visit: www.colveratest.com and www.clinicalgenomics.com.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.